Int J Mol Sci 2020;21:4003.ArticlePubMedPMC 11
The researchers evaluated the treatment status of GLP-1 users every six months
Clinical Implications Beyond Diabetes and Obesity While retatrutide is being tested primarily for obesity and type 2 diabetes , its impact on LDL suggests future use in: Cardiovascular disease prevention (alongside statins or in statin-intolerant patients) Metabolic syndrome management Nonalcoholic fatty liver disease (NAFLD/NASH) , since LDL and triglyceride metabolism are central to liver health Complementary to Statins Unlike statins, which only reduce LDL synthesis, retatrutide may work through multiple lipid pathways , making it synergistic rather than redundant
We know these aren't altogether new ideas, but we find that understanding the why behind them helps them stick
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice
and European markets, Lilly and Novo appear to be pushing for sales of their GLP-1 drugs in China
